HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO CanSino Biologics - 2022 Annual Results May Be Ugly as MCV4 Commercialization Hit a Snag

Pre-IPO New Ruipeng Pet Group (RPET.US)- The Industry, the Business and the Concerns

I-Mab (IMAB.US) - An "Entertaining Bet": To Be a Dark Horse or to Fail Completely

Modern Dental Group (3600.HK)- 2023 Harsh Reality Is Hard to Avoid, but Short-Term Rally Is Possible

Angelalign Technology (6699.HK) - There Is Still Plenty of Downside, but Limited Upside Potential

Angelalign Technology (6699.HK) 22H1 - Still “Bubble” in Valuation; The Era of High Margin Is Over

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Angelalign Technology  / Equity Bottom-Up

<ul>
<li>The rebound of Angelalign's share price isn’t based on the reversal of its fundamentals,but increasing confidence in China's economic recovery. Investors could take the opportunity to trade during this time.</li>
<li>It’s “a helpless move” for Angelalign to participate in centralized procurement. The price change brought about by centralized procurement would weaken the brand advantage of leading manufacturers and change consumers’  preferences.</li>
<li>We are not optimistic about Angelalign’s 2022 performance. Its performance in 2023 could still be lower-than-expected after China reopens. When COVID-19 is no longer an excuse, true color reveals. </li>
</ul>


The rebound of Angelalign's share price isn’t based on the reversal of its fundamentals,but increasing confidence in China's economic recovery. Investors could take the opportunity to trade during this time.
It’s “a helpless move” for Angelalign to participate in centralized procurement. The price change brought about by centralized procurement would weaken the brand advantage of leading manufacturers and change consumers’  preferences.
We are not optimistic about Angelalign’s 2022 performance. Its performance in 2023 could still be lower-than-expected after China reopens. When COVID-19 is no longer an excuse, true color reveals. 


Angelalign Technology (6699.HK) - About the Share Price Rebound, the Outlook and the Challenges